Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380100 | 0.85 | HDAC1 (0.61) | KEAP1TDP1HDAC2HDAC8HDAC6 | |
| SCHEMBL17288773 | 0.83 | MAPT (0.61) | TDP1HDAC2HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL17288634 | 0.81 | MAPT (0.64) | HDAC2HDAC8HDAC6SMN1; SMN2HDAC1 | |
| SCHEMBL17288871 | 0.81 | MAPT (0.64) | HDAC2HDAC8HDAC6SMN1; SMN2HDAC1 | |
| SCHEMBL17288948 | 0.81 | MAPT (0.64) | HDAC2HDAC8HDAC6SMN1; SMN2HDAC1 | |
| SCHEMBL1498978 | 0.80 | KEAP1 (0.67) | KEAP1ALDH1A1FFAR1TDP1HDAC2 | |
| SCHEMBL10049328 | 0.80 | KEAP1 (0.54) | KEAP1ALDH1A1FFAR1TDP1HDAC2 | |
| SCHEMBL28200575 | 0.80 | KEAP1 (0.54) | KEAP1ALDH1A1FFAR1TDP1HDAC2 | |
| SCHEMBL8665089 | 0.78 | KEAP1 (0.64) | KEAP1ALDH1A1FFAR1TDP1HDAC2 | |
| SCHEMBL4141193 | 0.78 | KEAP1 (0.64) | KEAP1ALDH1A1FFAR1TDP1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | claimed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | claimed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | claimed |
| US-6451833-B1 | ANGIOTENSIN ANTAGONISTS | PHARMACIA CORPORATION | 2002-09-17 | — | — | US | claimed |
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | claimed |
| US-6008368-A | USEFUL FOR TREATING HYPERTENSION AND CONGESTIVE HEART FAILURE; NONPEPTIDIC | G. D. SEARLE & CO. (US) | 1999-12-28 | — | — | US | claimed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | claimed |
| US-5643906-A | LOWERING INTRAOCULAR PRESSURE FOR TREATMENT OF GLAUCOMA | G.D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | claimed |
| EP-0508445-A1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | claimed |
| US-5155117-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1992-10-13 | — | — | US | claimed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | claimed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1992015577-A1 | N-SUBSTITUTED (ALPHA-IMIDAZOLYL-TOLUYL) PYRROLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | claimed |
| US-5140036-A | Hypotensive agents; congestive heart failure; angiotensin antagonists | G. D. SEARLE & CO. (US) | 1992-08-18 | — | — | US | claimed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | claimed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | claimed |
| WO-1992005161-A1 | 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | KEAP1 1533/4885ALDH1A1 4174/4885FFAR1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.